Scemblix (asciminib) — United Healthcare

Initial criteria

• Diagnosis of myeloid/lymphoid neoplasm with eosinophilia and ABL1 rearrangement
• AND Disease is in chronic or blast phase

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Scemblix therapy

Approval duration

12 months